AlClin is the oldest known manufacturer of NAD+ and has exclusively focused on NAD+ since 1974 with a long history of accumulated know-how and deep domain expertise.
50 Years of Cumulated Know How; Alclin’s Craft is based in Research and First Hand Observation
THE ALCLIN STORY
Christo Coetzee is the founder and CEO of AlClin Pharmaceuticals, a driven and passionate health advocate. In 1982, he started his career at Covan Pharmaceuticals (PTY) Ltd as a laboratory technician and was consistently promoted until becoming CEO by 1990. Acting as CEO, Covan Pharmaceuticals was sold to Adcock Ingram (formerly Zurich Pharma) in 1994. Mr. Coetzee maintained ownership of the NAD IV product that was being manufactured then and started Alclin (PTY) Ltd to continue production on the NAD vials and invest more time and resources into the research and development of NAD products. The NAD+ was trademarked in 1974 as DPN (Diphosphopyradine Nucleotide) by Christo’s father Ernst Pieter Coetzee.
Christo Coetzee pictured with his daughter on her wedding day.
NAD+
[ nicotinamide adenine dinucleotide ]
NAD+ is naturally occurring in mammals and is an essential housekeeping molecule found in every cell of the body; it is as vital to our bodies as oxygen.
NAD+ serves as a co-factor and driving force for various critical cellular processes, such as energy metabolism, mitochondrial function, biosynthesis, gene expression, DNA repair, immune function and aging.
NAD+ diminishes with age. The decline of NAD+ levels is the scientific trigger for the decline of many basic physiological functions that lead to early aging and potentially chronic diseases. Administration of NAD+ assists with the mitigation of such risks.
The market for NAD+ is projected to exceed US$1.4BN by 2030
ALCLIN USPs
Oldest known producer of NAD+, now in its third generation of family ownership, management and operations.
Registered Pharmaceutical Manufacturer (not a compounding pharmacist) producing a pharmaceutical product (not a compounded product).
Exclusive focus on NAD+. No mixing with other preparations. Eliminating cross-product contamination risks.
Batch producer, each batch with own Certificate of Analysis.
Decades of experience iterating to find best in class raw material: Always pyrogen-free and heavy metals tested and that complies to all criteria in pharmacopeias.
Liquid in a vial format is stable for 18 months at 2-8 Celsius (versus other product which deteriorates within a few weeks).
Pre-production: All steps (including continuous environmental monitoring, decontamination considerations and all other steps as required in Annex 1 of cGMP-set standards).
Post-production steps: All steps are followed as prescribed in Annex 1 of cGMP (including full sterility, pyrogen, stability and visual inspection tests).
